EVER2 Antibody

EVER2 Antibody

Catalog# : 4657

Epidermodysplasia verruciformis (EV) is an autosomal recessive genodermatosis associated with a high risk of skin cancers resulting from a high susceptibility to infection by specific human papillomaviruses. Mutations in two homologous genes EVER1 and EVER2 cause the majority of EV cases. These two proteins form a complex and interact with the zinc transporter ZnT-1 in the endoplasmic reticulum. Cells lacking EVER2 accumulated higher levels of zinc in the nucleolus and nucleus compare to those cells with and intact EVER2 gene, indicating that one role of EVER2 is to regulate the intracellular distribution of zinc. At least two isoforms of EVER2 are known to exist; this antibody will only recognize the larger isoform. EVER2 has no cross-reactivity to EVER1.
Additional Names : EVER2 (NT), Transmembrane channel-like protein 8, TMC8

Description
Left: Western blot analysis of EVER2 in rat thymus tissue lysate with EVER2 antibody at (A) 1 and (B) 2 µg/ml.





Source : EVER2 antibody was raised against a 18 amino acid peptide from near the amino terminus of human EVER2.
Purification : Affinity chromatography purified via peptide column
Clonality and Clone : This is a polyclonal antibody.
Host : EVER2 antibody was raised in rabbit. Please use anti-rabbit secondary antibodies.
Application : EVER2 antibody can be used for detection of EVER2 by Western blot at 1 – 2 µg/ml.
Tested Application(s) : E, WB
Buffer : Antibody is supplied in PBS containing 0.02% sodium azide.
Blocking Peptide : Cat.No. 4657P - EVER2 Peptide
Long-Term Storage : EVER2 antibody can be stored at 4ºC, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Positive Control
1. Cat. No. 1471 - Rat Thymus Tissue Lysate
Species Reactivity :H, M, R
GI Number : 25527192
Accession Number : AAM44454
Short Description : Transmembrane channel-like protein 8
References
1. Ramoz N, Taieb A, Rueda L-A, et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J. Invest. Dermatol. 2000; 114:1148-53.
2. Ramoz N, Rueda L-A, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat. Genet. 2002; 32:579-81.
3. Lazarczyk M, Pons C, Mendoza J-A, et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J. Exp. Med. 2008; 205:35-42.